Real-world progression-free survival of patients on anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) for ALK+ non-small cell lung cancer (NSCLC)

Authors :: Mohammad Jahanzeb
Huamao Mark Lin
A. Desai
X. Pan
Mark A. Socinski
Y. Yin
B.L. Nordstrom
Peijie Hou
Source :: Annals of Oncology. 29:viii504
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Oncology
business.industry
Cancer research
Medicine
Anaplastic lymphoma kinase
non-small cell lung cancer (NSCLC)
Hematology
Progression-free survival
business
medicine.disease
Tyrosine kinase

Full Text Access

Tools